menu
    • menu
    [{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Photocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Photocure","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Photocure"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Aminolevulinic Acid Hexylester

    Menu

    Aminolevulinic Acid Hexylester

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asieris Announces NDA Acceptance for Regulatory Review of Cevira in China

                            Details : APL-1702 (cevira) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions, licensed to Asieris by Photocure.

                            Product Name : Cevira

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 05, 2024

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Photocure

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has A...

                            Details : Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

                            Product Name : Cevira

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 20, 2023

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Photocure

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development an...

                            Details : APL-1702 (trade name: Cevira®), a drug-device combination photodynamic therapy product for non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL) caused by any HPV subtypes.

                            Product Name : Cevira

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 25, 2022

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            APL-1702 International Multicenter Phase III Clinical Trial of the First Patient in Asia Hong

                            Details : APL-1702 (Cevira ® ) is a photodynamic drug device combination product. Based on the principle of photodynamics, it combines a photosensitizer with a specific wavelength of light activation to produce a therapeutic effect.

                            Product Name : Cevira

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 11, 2020

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Asieris Pharmaceuticals

                            China arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervic...

                            Details : Asieris has received Clinical Trial Approval from China NMPA for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product Cevira®, which is being developed for the non-surgical treatment of high-grade cerv...

                            Product Name : Cevira

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 07, 2020

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth